FDA’s Focus Returns to Compounding and Telehealth: Another Wave of Warning Letters

Short summary

FDA issued 25 warning letters in June 2026 for misleading telehealth GLP-1 marketing, continuing enforcement that hit 175+ letters since September 2025. Violations include false 'generic' claims, implied FDA approval, equivalence messaging, and pharmacy misrepresentation. Enforcement reflects 1,700+ adverse events from compounded semaglutide/tirzepatide.

• •FDA issued 25 warning letters in June 2026 targeting telehealth companies for misleading GLP-1 compounded drug claims
• •Third enforcement wave since September 2025; total 175+ warning/untitled letters issued across all rounds
• •Key violations: false 'generic' framing, implied FDA approval, equivalence claims, and sourcing misrepresentation

Generated with AI, which can make mistakes.